首页> 外国专利> GENE-THERAPY DNA-VECTOR BASED ON GENE-THERAPY DNA-VECTOR VTVAF17, CARRYING TARGET GENE SELECTED FROM GROUP OF GENES BMP-2, BMP-7, LMP-1, NELL-1 TO INCREASE EXPRESSION LEVEL OF THESE TARGET GENES, METHOD FOR PRODUCTION AND APPLICATION THEREOF, STRAIN ESCHERICHIA COLI SCS110-AF/VTVAF17-BMP-2, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-BMP-7, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-LMP-1, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-NELL-1, CARRYING GENE-THERAPY DNA VECTOR, METHOD FOR PRODUCTION THEREOF, METHOD FOR INDUSTRIAL PRODUCTION OF GENE-THERAPY DNA VECTOR

GENE-THERAPY DNA-VECTOR BASED ON GENE-THERAPY DNA-VECTOR VTVAF17, CARRYING TARGET GENE SELECTED FROM GROUP OF GENES BMP-2, BMP-7, LMP-1, NELL-1 TO INCREASE EXPRESSION LEVEL OF THESE TARGET GENES, METHOD FOR PRODUCTION AND APPLICATION THEREOF, STRAIN ESCHERICHIA COLI SCS110-AF/VTVAF17-BMP-2, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-BMP-7, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-LMP-1, OR ESCHERICHIA COLI SCS110-AF/VTVAF17-NELL-1, CARRYING GENE-THERAPY DNA VECTOR, METHOD FOR PRODUCTION THEREOF, METHOD FOR INDUSTRIAL PRODUCTION OF GENE-THERAPY DNA VECTOR

机译：基于基因治疗DNA-载体VTVAF17的基因治疗DNA-载体，携带选自基因组BMP-2，BMP-7，LMP-1，NELL-1的靶基因以增加这些靶基因的表达水平，方法应变大肠埃希氏菌SCS110-AF / VTVAF17-BMP-2或大肠埃希氏菌SCS110-AF / VTVAF17-BMP-7或大肠埃希氏菌SCS110-AF / VTVAF17-LMP-1或大肠埃希氏菌SCS110-AF的生产和应用/ VTVAF17-NELL-1，携带基因治疗DNA矢量，其制备方法，工业生产基因治疗DNA矢量的方法

页面导航

摘要
著录项
相似文献

摘要

FIELD: biotechnology; medicine; agriculture.;SUBSTANCE: invention refers to genetic engineering and can be used in biotechnology, medicine and agriculture to develop gene therapy preparations. Gene-therapy DNA vector based on the gene-therapy DNA vector VTvaf17, having a target gene selected from the group of genes BMP-2, BMP-7, LMP-1, NELL-1, is created to increase the level of expression of this target gene in the human and animal body, wherein the gene-therapy DNA vector VTvaf17-BMP-2, or VTvaf17-BMP-7, or VTvaf17-LMP-1, or VTvaf17-NELL-1 has the nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, respectively. Each of the created gene-therapy DNA vectors: VTvaf17-BMP-2, or VTvaf17-BMP-7, or VTvaf17-LMP-1, or VTvaf17 NELL-1 due to the limited size of the vector part VTvaf17, not exceeding 3200 base pairs, is able to efficiently penetrate into cells and to express a target gene cloned in it, selected from a group of genes BMP-2, BMP-7, LMP-1, NELL-1 respectively.;EFFECT: gene-therapy DNA-vector contains no nucleotide sequences of viral origin and antibiotic-resistant genes are absent, providing the possibility of its safe application for genetic therapy of human and animals.;14 cl, 15 dwg, 20 ex

机译：领域：生物技术;药物;物质：发明是指基因工程，可以用于生物技术，医学和农业中以开发基因疗法的制剂。创建基于基因治疗DNA载体VTvaf17的基因治疗DNA载体，其具有选自基因BMP-2，BMP-7，LMP-1，NELL-1的靶基因，以提高其表达水平。人和动物体内的该靶基因，其中基因治疗DNA载体VTvaf17-BMP-2或VTvaf17-BMP-7或VTvaf17-LMP-1或VTvaf17-NELL-1具有核苷酸序列SEQ ID No或SEQ ID No.2或SEQ ID No.3或SEQ ID No.4。每个创建的基因治疗DNA载体：VTvaf17-BMP-2或VTvaf17-BMP-7或VTvaf17-LMP-1或VTvaf17 NELL-1，因为载体部分VTvaf17的大小有限，不超过3200个碱基对，能够有效渗入细胞并表达克隆到其中的靶基因，分别选自基因BMP-2，BMP-7，LMP-1，NELL-1。效果：基因治疗DNA-该载体不含病毒来源的核苷酸序列，并且缺少抗生素抗性基因，为将其安全用于人和动物的基因治疗提供了可能性。; 14 cl，15 dwg，20 ex

著录项

公开/公告号RU2720521C1

专利类型
公开/公告日2020-04-30

原文格式PDF
申请/专利权人 CELL AND GENE THERAPY LTD;
展开▼

申请/专利号RU20180142244
发明设计人 SAVELIEVA NATALIA (AT);
展开▼

申请日2018-11-29
分类号C12N15;
国家 RU
入库时间 2022-08-21 11:02:29

相似文献

专利
外文文献